Authored By: Sarah
11 Jul 2024

 Premature Ejaculation Treatment Market Size to grow by USD 1459.85 million between 2024-2028

According to a research report “ Premature Ejaculation Treatment Market” by Route Of Administration (Oral, Topical) Drug Class (SSRIs, PDE5 inhibitors, Amide anesthetics, Others) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 1459.85 million, at a CAGR of  8.78% during the forecast period. The global market for premature ejaculation treatment is characterized by a limited number of approved products, with off-label drugs, generic versions of patent-expired medications, and over-the-counter formulations dominating the landscape. The increasing demand for off-label treatments, particularly those derived from Selective Serotonin Reuptake Inhibitors (SSRIs) and Phosphodiesterase 5 (PDE5) inhibitors, is driving market growth. SSRIs, which are primarily used to treat depression and mental health disorders, have gained popularity due to their ability to delay ejaculation in men. Notably, PDE5 inhibitors, initially developed for erectile dysfunction, have also shown promise in the treatment of premature ejaculation. The use of these off-label drugs has significantly transformed the therapeutic approach to this condition.

Browse market data tables, figures, and in-depth TOC on “Premature Ejaculation Treatment Market” by Route Of Administration (Oral, Topical) Drug Class (SSRIs, PDE5 inhibitors, Amide anesthetics, Others) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample


By Route Of Administration, the Oral segment is projected to dominate the market size in 2024

In the global market for premature ejaculation treatment, selective serotonin reuptake inhibitors (SSRIs) hold a significant market share due to their efficacy in addressing this condition. SSRIs, which can be prescribed individually or in conjunction with other drug classes, such as antidepressants, function by modifying the regulation of serotonin in the central nervous system. Serotonin, a crucial neurotransmitter, has been identified as having the greatest impact on ejaculation and timing. Clinical investigations have substantiated this notion, leading to the widespread use of SSRIs in managing premature ejaculation.

By Drug Class, SSRIs  segment is expected to hold the largest market size for the year 2024

The oral route segment holds a substantial market share in the premature ejaculation treatment industry due to the convenience and widespread acceptance of oral medications as an initial treatment option. These drugs, available in forms such as tablets, capsules, and liquids, have gained popularity for their ease of use and accessibility. Traditional treatments like alpha aminobenzoate and phenoxybenzamine, which were previously used to prolong coitus, were discontinued due to their severe side effects. Subsequently, tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) were adopted for their sustained efficacy in enhancing ejaculatory latency and manageable side effect profiles. The mechanism of action for delayed ejaculation with SSRIs is believed to be linked to the inhibition of multiple descending pathways involved in the ejaculatory reflex.

North America is forecasted to hold the largest market size by region in 2024

The North American region holds a dominant position in the global premature ejaculation (PE) treatment market, driven by a substantial increase in PE cases due to psychological stress and lifestyle changes. PE is a prevalent sexual disorder among men under 40 years old, making the US market particularly significant. Leading industry players, such as Innovus Pharmaceuticals and Absorption Pharmaceuticals, are based in North America and are actively participating in the market. Innovus Pharmaceuticals has already introduced PE drugs like EjectDelay, while Absorption Pharmaceuticals' FORTACIN (PSD502 or Tempe spray) is pending US FDA approval for launch.

The Premature Ejaculation Treatment Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Absorption Pharmaceuticals LLC
  • Alembic Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals Inc.
  • Aytu BioPharma Inc.
  • Bayer AG
  • Eli Lilly and Co.
  • Futura Medical plc
  • GlaxoSmithKline Plc
  • Johnson and Johnson
  • LloydsPharmacy
  • Morari Inc.
  • NeuroHealing Pharmaceuticals Inc.
  • Niksan Pharmaceutical
  • Pfizer Inc.
  • Plethora Solutions Ltd.
  • Prinston Pharmaceutical Inc.
  • Ralington Pharma LLP
  • Sunrise Remedies Pvt. Ltd.
  • Tabuk Pharmaceuticals
  • Veru Inc.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Premature ejaculation (PE) is a common sexual health issue characterized by the incapability to control ejaculation during sexual intercourse, leading to distress and dissatisfaction for individuals and their partners. PE can be classified as Acquired or Lifelong, depending on when it starts. Treatment options for PE include behavioral techniques, medication, and diagnostic methods. Dapoxetine, marketed as Westoxeti, is a selective serotonin reuptake inhibitor (SSRI) with a short half-life, specifically developed for the treatment of PE. It works by increasing the time before ejaculation occurs during sexual activity. However, side effects such as nausea, dizziness, and headaches may occur. Clinical trials have shown that Dapoxetine is effective in delaying ejaculation, allowing for more sexual pleasure and satisfaction during intercourse. However, travel restrictions due to its prescription status and potential interaction with other medications require careful planning and medical assistance. Behavioral techniques, such as the stop-start method and the squeeze technique, can also be effective in managing PE. These methods aim to increase sensitivity and control over ejaculation. It is essential to consult a healthcare professional for a proper diagnosis and treatment plan for PE, as it can impact the quality of sexual encounters and overall sexual health. Diagnostic methods may include a medical history, physical examination, and sexual function assessment.

Market Research Overview

Premature ejaculation (PE) is a common sexual health issue characterized by the inability to control ejaculation during intercourse, leading to significant distress and dissatisfaction for individuals and their partners. The global market for PE therapeutics is expanding, offering various treatments to address this concern. Therapeutic interventions include medications like Fortacin, Dapoxetine (Brand names: Westoxeti, Zertane), and local anesthetics applied to the penis. Behavioral therapies, such as squeeze technique, are also effective. However, limitations include insomnia, fatigue, somnolence, diarrhea, headache, dizziness, and nausea as side effects. Planning for PE treatments includes understanding the half-life, intercourse timings, and potential interactions with other medications. Companies like Vivus, Torrent Pharma, Sunrise Pharma, Teva, Menarini, Bayer, GlaxoSmithKline, and Eli Lilly are major players in this market. Alternative treatment methods include FDA-approved devices like Prolong, clinical trials of Tramadol hydrochloride, and diagnostic tools. Strategic collaborations and launches of new treatments, such as Promescent, continue to evolve the landscape. PE's prevalence rate is high, affecting both acquired and lifelong cases, and is linked to biological and psychological factors, including anxiety, depression, poor body image, and sexual abuse. Early sexual experiences and inherited traits can also contribute. PE treatments may face challenges due to clinical trial delays, shortages, and resource constraints, as well as travel restrictions and diagnostic method limitations. Telemedicine and digital health platforms offer potential solutions for access to medical assistance. PE is not just a sexual issue; it can impact overall well-being. Effective treatments can help individuals regain control and improve their sexual pleasure and satisfaction.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Read News Read Less
Interested in this report?
Get your sample now!